nach oben

International Journal of Clinical Oncology

Erschienen in:

01.08.2015 | Original Article

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

verfasst von: Ryo Ko, Hirotsugu Kenmotsu, Yasushi Hisamatsu, Hiroaki Akamatsu, Shota Omori, Kazuhisa Nakashima, Takuya Oyakawa, Kazushige Wakuda, Takehito Shukuya, Akira Ono, Hisao Imai, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Keita Mori, Masahiro Endo, Yasuhisa Ohde, Kazuhisa Takahashi, Toshiaki Takahashi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

It is unclear whether there is a difference in the effect of gefitinib treatment between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and those with stage IV NSCLC harboring mutations in the epidermal growth factor receptor (EGFR).

Methods

We retrospectively reviewed the medical records of consecutive patients with postoperative recurrent NSCLC (postoperative group) or stage IV NSCLC (stage IV group) harboring EGFR mutations who were treated with gefitinib at the Shizuoka Cancer Center between September 2002 and March 2012 to compare the effect of gefitinib on survival from treatment initiation.

Results

A total of 168 patients were treated with gefitinib (postoperative group, 49 patients; stage IV group, 119 patients). The response rate of gefitinib treatment in the postoperative group was similar to that in the stage IV group (58 vs. 61 %, p = 0.613). In contrast, median progression-free survival (PFS; 15.8 vs. 9.8 months, p < 0.001) and median overall survival (OS; 51.1 vs. 22.2 months, p < 0.001) were significantly longer in the postoperative group. In addition, postoperative recurrent disease, performance status (0–1), and a single metastatic organ were independent favorable prognostic factors in the multivariate analysis of survival.

Conclusions

PFS and OS were superior in patients with postoperative recurrent NSCLC harboring EGFR mutations treated by gefitinib than in those with stage IV disease. These results suggest that postoperative recurrent disease may be considered a stratification factor in clinical trials for NSCLC with EGFR mutations.

Scagliotti GV, Fossati R, Torri V et al (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1453–1461PubMedCrossRef

Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRef

Sugimura H, Nichols FC, Yang P et al (2007) Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 83:409–418PubMedCrossRef

Saisho S, Yasuda K, Maeda A et al (2013) Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg 16:166–172PubMedCentralPubMedCrossRef

Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817–1824PubMedCrossRef

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef

Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128PubMedCrossRef

Eisenhauser EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef

Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521PubMedCrossRef

10.

Hoang T, Xu R, Schiller JH et al (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 23:175–183PubMedCrossRef

11.

Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892PubMedCrossRef

12.

Taniguchi K, Okami J, Kodama K et al (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99:929–935PubMedCrossRef

13.

Inukai M, Toyooka S, Ito S et al (2006) Presence of epidermal growth factor receptor gene T790 M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66:7854–7858PubMedCrossRef

14.

Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77–88PubMedCentralPubMedCrossRef

15.

Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13:e178–e185PubMedCrossRef

16.

Park JH, Kim TM, Keam B et al (2013) Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin Lung Cancer 14:383–389PubMedCrossRef

17.

Liao S, Penney BC, Wroblewski K et al (2012) Prognostic value of metabolic tumor burden on 18 F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39:27–38PubMedCrossRef

18.

Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259PubMedCrossRef

19.

Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185:60–66PubMedCrossRef

20.

Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659PubMedCrossRef

21.

Kawano D, Takeo S, Katsura M et al (2012) Surgical treatment of stage IV non-small cell lung cancer. Interact Cardiovasc Thorac Surg 14:167–170PubMedCentralPubMedCrossRef

22.

Hanagiri T, Takenaka M, Oka S et al (2012) Results of a surgical resection for patients with stage IV non-small-cell lung cancer. Clin Lung Cancer 13:220–224PubMedCrossRef

23.

Hishida T, Nagai K, Mitsudomi T et al (2010) Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg 140:e69–e71PubMedCrossRef

24.

Sculier JP, Chansky K, Crowley JJ et al (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 3:457–466PubMedCrossRef

25.

Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618–1626PubMed

26.

Wakelee HA, Bernardo P, Johnson DH et al (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)—comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106:2208–2217PubMedCrossRef

27.

Janjigian YY, McDonnell K, Kris MG et al (2010) Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 116:670–675PubMedCentralPubMedCrossRef

Titel: The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
verfasst von: Ryo Ko
Hirotsugu Kenmotsu
Yasushi Hisamatsu
Hiroaki Akamatsu
Shota Omori
Kazuhisa Nakashima
Takuya Oyakawa
Kazushige Wakuda
Takehito Shukuya
Akira Ono
Hisao Imai
Tetsuhiko Taira
Tateaki Naito
Haruyasu Murakami
Keita Mori
Masahiro Endo
Yasuhisa Ohde
Kazuhisa Takahashi
Toshiaki Takahashi
Publikationsdatum: 01.08.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0761-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor